1 Introduction Significant advances in mRNA technology have enabled the rapid and efficient programmed design and manufacturing of functional proteins.[1] This versatility has driven the use of mRNA in diverse immunotherapeutic approaches, particularly in the context of cancer immunotherapy.[2] mRNA-based cancer immunotherapy, involving vaccines encoding tumor antigens and immune modulators, has shown promise in both preclinical and clinical studies.[3] Furthermore, recent endeavors have...
